COVID-19 Update: We are committed to providing eye care in a safe environment for our patients and staff during these challenging times.View our safety procedures video
Mid Atlantic Retina-Wills Eye Hospital has been named the lead center of 60 centers, for the first pivotal trial for Wet AMD. Dr. Allen Ho will serve as the lead investigator for the trial program. Recently, positive preliminary long term data in RGX-314 gene therapy for Wet AMD and embark upon the first pivotal trial of gene therapy for the treatment of Wet AMD – the Atmosphere pivotal trial.
”I am excited about this data out to three years, which demonstrates that one-time treatment with RGX-314 has the potential to result in long-term stability to improvement of visual acuity outcomes and retinal anatomy, while alleviating treatment burden,” said Allen C. Ho, M.D., Director of Retina Research at Wills Eye Hospital and Mid Atlantic Retina and investigator surgeon in the RGX-314 clinical trials. “In our practice, and as reported by multiple real-world studies, we see many patients losing vision due to lack of compliance with standard of care, which requires frequent anti-VEGF injections. I look forward to further evaluating the effects of RGX-314 in ATMOSPHERE, the first pivotal trial of a gene therapy for the treatment of wet AMD.”